ReviewWorld journal of gastroenterology2014
Potential prognostic, diagnostic and therapeutic markers for human gastric cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Construction of an immune-related risk score signature for gastric cancer based on multi-omics data.Scientific reports · 2024Article
- Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.Stem cells international · 2024Review
- Prognostic significance of metastatic lymph node ratio in gastric cancer: a Western-center analysis.BMC surgery · 2023Article
- PharmaKoVariome database for supporting genetic testing.Database : the journal of biological databases and curation · 2022Article
- Molecular and Circulating Biomarkers of Gastric Cancer.International journal of molecular sciences · 2022Review
- Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK.Molecular medicine reports · 2018Article
- Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.Oncotarget · 2018Review
- Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer.Clinical proteomics · 2018Article
- Recent advances in mass spectrometry-based proteomics of gastric cancer.World journal of gastroenterology · 2016Review
- A long non-coding RNA signature to improve prognosis prediction of gastric cancer.Molecular cancer · 2016Article
- Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.Scientific reports · 2016Article
- Upregulated long intergenic noncoding RNA KRT18P55 acts as a novel biomarker for the progression of intestinal-type gastric cancer.OncoTargets and therapy · 2016Article
- AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells.Molecular and cellular biochemistry · 2016Article
- Cullin family proteins and tumorigenesis: genetic association and molecular mechanisms.Journal of Cancer · 2015Review
- Methylation status of TRAF2 is associated with the diagnosis and prognosis of gastric cancer.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high incidence of gastric cancer (GC) and its consequent mortality rate severely threaten human health. GC is frequently not diagnosed until a relatively advanced stage. Surgery is the only potentially curative treatment. Thus, early screening and diagnosis are critical for improving prognoses in patients with GC. Gastroscopy with biopsy is an appropriate method capable of aiding the diagnosis of specific early GC tumor types; however, the stress caused by this method together with it being excessively expensive makes it difficult to use it as a routine method for screening for GC on a population basis. The currently used tumor marker assays for detecting GC are simple and rapid, but their use is limited by their low sensitivity and specificity. In recent years, several markers have been identified and tested for their clinical relevance in the management of GC. Here, we review the serum-based tumor markers for GC and their clinical significance, focusing on discoveries from microarray/proteomics research. We also review tissue-based GC tumor markers and their clinical application, focusing on discoveries from immunohistochemical research. This review provides a brief description of various tumor markers for the purposes of diagnosis, prognosis and therapeutics, and we include markers already in clinical practice and various forthcoming biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.